Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Broad ChemoCentryx Inflammation Alliance Plants CEEDD Downstream

This article was originally published in Start Up

Executive Summary

ChemoCentryx's broad deal with GSK's Center for Excellence in External Drug Discovery (CEEDD) moves CEEDD downstream into early clinical territory and sets the biotech up for a potential IPO. The deal also illustrates the difficulties in defining alliance parameters like proof-of-concept.

You may also be interested in...



GSK's Risk-Sharing Deals to Compete with In-House R&D

Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.

Theravance: Having Cake and Eating It

Thanks to productivity, lower-risk follow-on drugs and access to a Big Pharma balance sheet, Theravance is trying to demonstrate the possibility of getting paid for doing what biotech does best: research.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091296

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel